DLL3 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- DLL3 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100059
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- DLL3 antibody Polyclonal Antibodies Primary antibodies
Related genes to: DLL3 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- DLL3 NIH gene
- Name:
- delta like canonical Notch ligand 3
- Previous symbol:
- -
- Synonyms:
- SCDO1
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-03-15
- Date modifiied:
- 2018-04-25
Related products to: DLL3 antibody Polyclonal Antibodies Primary antibodies
Related articles to: DLL3 antibody Polyclonal Antibodies Primary antibodies
- Extensive-stage small-cell lung cancer (ES-SCLC) represents a highly aggressive neuroendocrine malignancy. While chemoimmunotherapy has improved initial prognosis, long-term survival is severely compromised by the rapid emergence of multifaceted resistance mechanisms, a challenge further compounded by the plateaued efficacy of traditional salvage therapies. As strategies aimed at reversing the immunologically "cold" phenotype encounter translational challenges, antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) targeting surface proteins such as DLL3 and B7-H3 are reshaping the therapeutic landscape via unique MHC-independent cytotoxicity. This review elucidates the molecular networks driving immune resistance and highlights clinical breakthroughs in these emerging modalities. Finally, we outline a strategic roadmap for next-generation precision oncology, integrating advantages of biomarkers in treatment, dynamic liquid biopsy for stratification, optimized toxicity management, and the leverage of reverse translation. - Source: PubMed
Publication date: 2026/05/31
Guan RuonanZhang ChenyueZhang JuntaoDu ShanshanWang HaoyuZhang YulinAbdi Abdi Aziz MohamedWang Haiyong - Lung cancer remains the leading cause of cancer-related death worldwide, with over two million new cases annually. Advances in molecular biology and immuno-oncology have fundamentally transformed treatment strategies. Comprehensive genomic profiling has enabled precision medicine approaches, allowing the selection of targeted therapies based on driver alterations such as , , and . For -mutant NSCLC, sequential development of tyrosine kinase inhibitors (TKIs) from first- to third-generation agents-culminating in osimertinib-has markedly improved survival. Similarly, successive generations of ALK inhibitors, including alectinib, brigatinib, and lorlatinib, have extended disease control, particularly within the central nervous system. The introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan for -mutant NSCLC, and emerging TKIs like zongertinib, represent new therapeutic milestones. Immunotherapy has become central to the management of both NSCLC and SCLC, with immune checkpoint inhibitors (ICIs) demonstrating unprecedented survival benefits. Beyond lung cancer, our group, in collaboration with Juntendo University ARO (academic research organization) and fifteen institutions in Japan, conducted the MARBLE phase II trial of atezolizumab plus chemotherapy for thymic carcinoma, achieving a 56% objective response rate and 9.6-month median progression-free survival, supporting potential ICI approval in Japan. Furthermore, novel immune strategies such as bispecific T-cell engagers (BiTEs) have shown promise. The DLL3-targeted BiTE tarlatamab significantly improved overall survival to 13.6 months in the phase III DeLLphi-304 trial for relapsed SCLC, with manageable cytokine release syndrome. Collectively, these advances signify a shift toward biologically driven, molecular-targeted or immune-integrated therapy, aiming to transform lung cancer into a chronic, manageable disease in the future, hopefully. - Source: PubMed
Publication date: 2026/03/04
Shukuya TakehitoTakahashi Kazuhisa - Small-cell prostate cancer (SCPC) is a rare, aggressive variant of prostate cancer with poor prognosis, arising "de novo" or through lineage plasticity from conventional adenocarcinoma under androgen receptor-targeted therapies. Characterized by low PSA levels despite high tumor burden and visceral metastases, SCPC poses diagnostic challenges with conventional and PSMA-targeted imaging due to variable tracer uptake. This narrative review aims to evaluate the role of PET/CT tracers in clinical and preclinical settings for SCPC diagnosis, staging, and management. - Source: PubMed
Publication date: 2026/05/20
Vocaturo FlaminiaTaralli SilviaScolozzi ValentinaLeccisotti LuciaCaldarella Carmelo - Small-cell lung cancer (SCLC) is one of the most aggressive subtype of lung carcinoma with limited treatment options. Delta-like ligand 3 (DLL3), a Notch ligand protein, has been an attractive target for SCLC due to its high expression on SCLC but limited expression on normal tissues. Here, we developed a bispecific T cell engager, IAR025, and investigated its antitumor efficacy against SCLC. IAR025 has a CD3 arm for T cell activation and a DLL3 arm for recognizing tumor cells with optimal affinity and binding domain. IAR025 resulted in a dose-dependent eradication of DLL3-positive SCLC cells, without nonspecific cell destruction in DLL3-negative cells in vitro. Administration of IAR025 in DMS79 and SHP-77 humanized mouse models significantly inhibited tumor growth. The mechanism study revealed that IAR025 treatment led to increased T-cell recruitment in tumors. IAR025 activity was further enhanced when combined with chemotherapy or anti-PD-1 treatment. In cynomolgus monkeys, IAR025 was well-tolerated at a dose up to 10 mg/kg and exhibited linear pharmacokinetics with a half-life of 90 h. Collectively, these preclinical results demonstrate that IAR025 is a highly potent therapeutic strategy for treating SCLC. - Source: PubMed
Publication date: 2026/05/26
Liu YangCao LeiXu MengqiuLi NinghuanZhang JianZhu MengjiaKuang ZhihuiSha HuijunWu MinXu JinlingWu ZhihaiFeng YeLi Li - Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous malignancies frequently resistant to standard therapies. Immunotherapy represents a novel management frontier. This review synthesises clinical and translational evidence regarding immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and oncolytic virotherapy in GEP-NENs. We examine critical antigenic targets (somatostatin receptors, DLL3) and strategies to overcome the immunosuppressive tumour immune microenvironment (TIME). While single-agent ICIs show modest efficacy in well-differentiated NETs, dual checkpoint blockade exhibits durable disease control in poorly differentiated NECs. Targeted modalities like DLL3-directed bispecific antibodies demonstrate significant early efficacy. Furthermore, we summarise highly synergistic combinatorial approaches, specifically integrating immunotherapy with anti-angiogenic agents and peptide receptor radionuclide therapy (PRRT). Ongoing biomarker-driven trials and molecular profiling remain essential to optimise patient selection and treatment sequencing. - Source: PubMed
Publication date: 2026/05/25
Chowdhury DurlavMishra ArunavaMuskan Rao MaikalaSahu RohanBodakhe Surendra H